[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@Prof_Oak_ Avatar @Prof_Oak_ Professor Oak

Professor Oak posts on X about $argx, $bmy, $270300m, $xbi the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks XXXX% finance XXXX% cryptocurrencies XXXX% currencies XXXX%

Social topic influence $argx 3.28%, $bmy #12, $270300m #1, $xbi #20, $bbc #3, bbc #565, cms 1.64%, $caba 1.64%, $kytx 1.64%, $cgem XXXX%

Top accounts mentioned or mentioned by @biopharmiq @learnbiotech @endpts @bowtiedbiotech @hall8jack @andrewedunn @skathire @vervetx @elilillyandco @balabioresearch @nellomainolfi @kymeratx @biotechtv @business @davidrliu @biohazard3737 @stephen_eades @crisprcio @crisprspace @captainrisky7

Top assets mentioned Bristol-Myers Squibb Co (BMY) Bitcoin Incognito (XBI) United Community Banks, Inc. (UCB) MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Eli Lilly and Company (LLY) Hims & Hers Health, Inc. (HIMS) BEAM (BEAM) Janux Therapeutics, Inc. Common Stock (JANX) Agios Pharmaceuticals, Inc. (AGIO) GOSSIP-COIN (GOSS) Immunovant, Inc. Common Stock (IMVT) BridgeBio Pharma, Inc. Common Stock (BBIO) Johnson & Johnson (JNJ) Alkermes Inc. plc (ALKS)

Top Social Posts #

Top posts by engagements in the last XX hours

"And then in a final assault on my hopes and dreams they told us 6MWT would be the Ph3 primary Hard to understand why a capable team if handed a drug that worked would ever be compelled to choose a Ph3 primary that: (A) is notoriously unpredictable (B) wasnt prospectively defined / disclosed in Ph1b (C) was informed by X pts of data (D) halves the trial-eligible portion of an already ultra-rare population"
X Link @Prof_Oak_ 2025-09-18T00:26Z 12K followers, 2663 engagements

"Its a disheartening new chapter in what had been a beautiful drug development story. Hoping for a win that benefits CMS pts everywhere but no conviction to be found here It's equally disheartening to see $ARGX stray from the rigor objectivity & discipline that have defined the company for so long Perhaps a one-off but wouldnt be the first time weve seen distorted R&D risk management incentives follow a mega-blockbuster success"
X Link @Prof_Oak_ 2025-09-18T00:26Z 12K followers, 2388 engagements

"CD19 CAR-T coming to IBD $CABA $KYTX $CGEM New N=1 case report from Schett describes clinical / biochemical remission achieved with auto CD19 CAr-T in refractory Ulcerative Colitis Can't find the article anywhere. potentially a bungled embargo Should be on NEJM soon enough"
X Link @Prof_Oak_ 2025-09-23T22:20Z 12K followers, 33.6K engagements

"Long live King Bime $UCB $MLTX UCB sub-$80 in April was such a gift"
X Link @Prof_Oak_ 2025-09-28T21:11Z 12K followers, 12K engagements

"In light of the Orbital / $BMY news worth revisiting $BEAM's remarkably productive track record in platform monetization (1) I estimate $270-300M of cash proceeds from the Orbital sale (2) Also used tech to seed $VERV & $PRME - still hold $6M / $9M of equity and monetized Verve Co/Co to $LLY for $200M U/F + $300M milestones (which are now much more likely pay out) (3) Capitalized on post-Covid $PFE to get $300M U/F for X discovery targets still the high-water mark in C&GTx (4) Got $75M U/F from $APLS for targets within a single pathway for which permanent editing will never make sense (5)"
X Link @Prof_Oak_ 2025-10-10T22:10Z 12K followers, 17K engagements

"When can I start buying this on $HIMS"
X Link @Prof_Oak_ 2025-09-22T14:06Z 12K followers, 393K engagements

"TD Cowen's top Q4 binaries with expected stock moves Happy hunting $XBI $BBC"
X Link @Prof_Oak_ 2025-10-01T06:29Z 12K followers, 24.8K engagements

"And yes $BEAM was -XXX% today despite Orbital effectively substituting for a follow-on. Here's how I got there: Aug X 2023 SEC correspondence notes $BEAM FD O/S of XXXX% pre-Series A PitchBook puts Orbital's Series A post at $702M - may not be perfect but probably close. With a bit of wiggle room for option pool expansion etc. current FD O/S lands at 18-20% On $1.5B U/F $270-300M into $BEAM's pocket Not bad"
X Link @Prof_Oak_ 2025-10-10T22:10Z 12K followers, 2399 engagements

"Last couple weeks have been electric. May the thunder roll into Q4 $XBI $BBC Some upcoming catalysts that are on my radar: $JANX PSMA / EGFR Ph1 $AGIO PKR SCD Ph3 $FULC SCD Ph1b $RZLT cHI Ph3 $GOSS PAH Ph3 $ZBIO IgG4-RD Ph3 $IMVT TED Ph3 $PVLA cVM Ph2 $BBIO ADH1 Ph3 / LGMD2i Ph3 IA $JNJ DUET IBD Ph2b $GPCR oGLP-1 Ph2b $CNTA OX2 NT1/2 & IH Ph2a $ALKS OX2 NT2 Ph2 $ALEC FTD-GRN Ph3 $BMY KarXT ADP Ph3 $SNY / $INBX AATD Ph2 $KRRO AATD Ph1 FIH $EWTX o/nHCM Ph1/2 $SRPT / $ARWR DM1 / FSHD Ph1 FIH $DYN Ex51 DMD Ph1/2 $RNA DM1 / DMD Ph1/2 OLE $RHBBY MSTN FSHD / SMA Ph2 $WVE / $ARWR INHBE Ph1/2 FIH"
X Link @Prof_Oak_ 2025-09-30T04:50Z 12K followers, 42.6K engagements

"Have followed $ARGX MuSK Agonist for years - simply b/c its an elegant scientific story (MOA inspired by autoAbs in MG) & the preclinical data are striking $ARGX announced Ph1b success in June along with bullish comments re: functional benefit Those data disclosed yesterday fail to match the description. Selective disclosure & perplexing development decisions - atypical for this company / team - further muddy the water It all feels shockingly non-Argenx and Im not sure what to make of it"
X Link @Prof_Oak_ 2025-09-18T00:26Z 12K followers, 7446 engagements